These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24806821)

  • 41. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
    Dagenais C; Zong J; Ducharme J; Pollack GM
    Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
    Jacobs S; McCully CL; Murphy RF; Bacher J; Balis FM; Fox E
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):817-24. PubMed ID: 19662415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
    He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
    Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
    Ohe T; Sato M; Tanaka S; Fujino N; Hata M; Shibata Y; Kanatani A; Fukami T; Yamazaki M; Chiba M; Ishii Y
    Drug Metab Dispos; 2003 Oct; 31(10):1251-4. PubMed ID: 12975334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
    Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
    Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Sadiq MW; Salehpour M; Forsgard N; Possnert G; Hammarlund-Udenaes M
    Drug Metab Dispos; 2011 Feb; 39(2):174-9. PubMed ID: 21059857
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery.
    Kalvass JC; Maurer TS
    Biopharm Drug Dispos; 2002 Nov; 23(8):327-38. PubMed ID: 12415573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.
    Zhou ZW; Chen X; Liang J; Yu XY; Wen JY; Zhou SF
    Drug Metab Lett; 2007 Aug; 1(3):205-17. PubMed ID: 19356045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insight into tissue unbound concentration: utility in drug discovery and development.
    Mariappan TT; Mandlekar S; Marathe P
    Curr Drug Metab; 2013 Mar; 14(3):324-40. PubMed ID: 23167621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model.
    Kosugi Y; Mizuno K; Santos C; Sato S; Hosea N; Zientek M
    AAPS J; 2021 May; 23(4):72. PubMed ID: 34008121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
    Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
    Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
    Caruso A; Alvarez-Sánchez R; Hillebrecht A; Poirier A; Schuler F; Lavé T; Funk C; Belli S
    Biochem Pharmacol; 2013 Jun; 85(11):1684-99. PubMed ID: 23454189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.
    Summerfield SG; Zhang Y; Liu H
    J Pharmacol Exp Ther; 2016 Aug; 358(2):294-305. PubMed ID: 27194478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of Subcutaneous and Intraperitoneal Administration Methods to Facilitate Cassette Dosing in Microdialysis Studies in Rats.
    Durk MR; Deshmukh G; Valle N; Ding X; Liederer BM; Liu X
    Drug Metab Dispos; 2018 Jul; 46(7):964-969. PubMed ID: 29700231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.
    Herukka SK; Rummukainen J; Ihalainen J; von Und Zu Fraunberg M; Koivisto AM; Nerg O; Puli LK; Seppälä TT; Zetterberg H; Pyykkö OT; Helisalmi S; Tanila H; Alafuzoff I; Hiltunen M; Rinne J; Soininen H; Jääskeläinen JE; Leinonen V
    J Alzheimers Dis; 2015; 46(1):261-9. PubMed ID: 25720406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.
    de Lange EC; Danhof M
    Clin Pharmacokinet; 2002; 41(10):691-703. PubMed ID: 12162757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of brain barriers in fluid movement in the CNS: is there a 'glymphatic' system?
    Abbott NJ; Pizzo ME; Preston JE; Janigro D; Thorne RG
    Acta Neuropathol; 2018 Mar; 135(3):387-407. PubMed ID: 29428972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
    Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates.
    Schou M; Varnäs K; Lundquist S; Nakao R; Amini N; Takano A; Finnema SJ; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2015 Mar; 18(10):pyv036. PubMed ID: 25813017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.